Nevro [NVRO] vs MaxCyte [MXCT] Detailed Stock Comparison

Nevro Corp.

NYSE
Loading...

MaxCyte Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Nevro Corp. wins in 9 metrics, MaxCyte Inc. wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Nevro Corp. MaxCyte Inc. Better
P/E Ratio (TTM) 144.40 -2.07 Nevro Corp.
Price-to-Book Ratio 0.96 0.55 MaxCyte Inc.
Debt-to-Equity Ratio 108.86 10.46 MaxCyte Inc.
PEG Ratio -2.26 0.21 MaxCyte Inc.
EV/EBITDA -2.15 -0.20 MaxCyte Inc.
Profit Margin (TTM) -27.77% -135.14% Nevro Corp.
Operating Margin (TTM) -21.79% -94.81% Nevro Corp.
Return on Equity -43.29% -23.63% MaxCyte Inc.
Return on Assets (TTM) -9.95% -12.60% Nevro Corp.
Free Cash Flow (TTM) $-29.23M $-36.18M Nevro Corp.
1-Year Return -56.06% -49.09% MaxCyte Inc.
Price-to-Sales Ratio (TTM) 0.55 2.88 Nevro Corp.
Enterprise Value $180.16M $7.89M Nevro Corp.
EV/Revenue Ratio 0.44 0.24 MaxCyte Inc.
Gross Profit Margin (TTM) 62.45% 77.95% MaxCyte Inc.
Revenue per Share (TTM) $11 $0 Nevro Corp.
Earnings per Share (Diluted) $-3.06 $-0.42 MaxCyte Inc.
Beta (Stock Volatility) 0.82 1.45 Nevro Corp.
Short % of Float N/A 5.23% N/A

Nevro Corp. vs MaxCyte Inc. Stock Performance Analysis

Loading Price Chart...

NVRO
MXCT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Nevro Corp.0.00%N/AN/AN/AN/AN/A
MaxCyte Inc.3.57%0.87%11.54%43.21%-22.15%-25.16%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Nevro Corp.-56.06%-92.38%-94.65%-89.12%-76.92%-76.92%
MaxCyte Inc.-49.09%-77.10%-93.41%-93.41%-93.41%-93.41%

Performance & Financial Health Analysis: Nevro Corp. vs MaxCyte Inc.

MetricNVROMXCT
Market Information
Market Cap i$224.09M$92.07M
Market Cap CategoryMicro capMicro cap
10 Day Avg. Volume i1,058,636734,696
90 Day Avg. Volume i1,147,389895,759
Last Close$5.84$1.16
52 Week Range$3.16 - $13.84$0.64 - $2.37
% from 52W High-57.80%-51.05%
All-Time High$188.14 (Dec 21, 2020)$17.44 (Jul 26, 2021)
% from All-Time High-96.90%-93.35%
Growth Metrics
Quarterly Revenue Growth-0.09%-0.16%
Quarterly Earnings Growth-0.09%-0.16%
Financial Health
Profit Margin (TTM) i-0.28%-1.35%
Operating Margin (TTM) i-0.22%-0.95%
Return on Equity (TTM) i-0.43%-0.24%
Debt to Equity (MRQ) i108.8610.46
Cash & Liquidity
Book Value per Share (MRQ)$6.11$1.61
Cash per Share (MRQ)$7.72$0.96
Operating Cash Flow (TTM) i$-19,439,000$-34,410,000
Levered Free Cash Flow (TTM) i$-4,766,875$-15,469,750
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Nevro Corp. vs MaxCyte Inc.

MetricNVRO (May 17, 2025)MXCT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i144.40-2.07
Forward P/E i-2.26-3.33
PEG Ratio i-2.260.21
Price to Sales (TTM) i0.552.88
Price to Book (MRQ) i0.960.55
Market Capitalization
Market Capitalization i$224.09M$92.07M
Enterprise Value i$180.16M$7.89M
Enterprise Value Metrics
Enterprise to Revenue i0.440.24
Enterprise to EBITDA i-2.15-0.20
Risk & Other Metrics
Beta i0.821.45
Book Value per Share (MRQ) i$6.11$1.61

Financial Statements Comparison: Nevro Corp. vs MaxCyte Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNVRO (2024)MXCT (2025)
Revenue/Sales i408.52M33.03M
Cost of Goods Sold i138.99M6.22M
COGS % of Revenue i34.0%18.8%
Gross Profit i269.53M26.80M
Gross Margin i66.0%81.2%
Research & Development i51.51M20.82M
Operating Income (EBIT) i-94.70M-45.29M
Operating Margin i-23.2%-137.1%
EBITDA i-67.70M-33.53M
EBITDA Margin i-16.6%-101.5%
Pre-Tax Income i-112.35M-44.63M
Pre-Tax Income % of Revenue i-27.5%-135.1%
Income Tax i1.09M0
Income Tax % of Revenue i0.3%0.0%
Net Income (Profit) i-113.44M-44.63M
Profit Margin i-27.8%-135.1%

Balance Sheet & Liquidity Metrics

MetricNVRO (2024)MXCT (2025)
Cash & Equivalents i94.54M20.07M
Total Current Assets i476.00M118.37M
Total Current Assets % of Revenue i116.5%358.4%
Total Current Liabilities i102.94M14.27M
Total Current Liabilities % of Revenue i25.2%43.2%
Long-Term Debt i213.19M16.49M
Long-Term Debt % of Revenue i52.2%49.9%
Total Shareholders Equity i231.01M171.49M
Retained Earnings i-812.85M-261.48M
Retained Earnings % of Revenue i-199.0%-791.7%
Property, Plant & Equipment i36.77M12.84M

Cash Flow Statement Comparison

MetricNVRO (2024)MXCT (2025)
Operating Cash Flow i-25.99M-35.79M
Operating Cash Flow % of Revenue i-6.4%-108.4%
Capital Expenditures i-9.79M-1.77M
Free Cash Flow i-29.23M-36.18M
FCF Margin i-7.2%-109.5%
Debt Repayment i0N/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNVROMXCT
Shares Short iN/A5.55M
Short Ratio iN/A5.36
Short % of Float iN/A5.23%
Shares Outstanding i37.82M106.79M
Float Shares i34.23M105.71M
% Held by Insiders i2.84%1.40%
% Held by Institutions i110.59%65.81%
% Held by Public i-13.43%32.79%

Dividend Analysis & Yield Comparison: Nevro Corp. vs MaxCyte Inc.

MetricNVROMXCT
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A